Clinical trial agreements (CTAs) are often treated as administrative documents, but in reality, they are one of the earliest opportunities to shape how liability will be allocated if something goes wrong.
At their core, CTAs define who is responsible for key aspects of trial conduct. But while contracts can allocate financial
responsibility between parties, they do not eliminate legal exposure. Sponsors continue to be viewed as the responsible party in the eyes of regulators and plaintiffs, particularly where they control protocol design, product development, and oversight of the trial.
This means that drafting your CTA is incredibly important. Indemnification provisions are typically the focal point of CTA negotiations, yet they can quietly expand exposure if they are not aligned with the actual risk profile of the study. Factors such as broad definitions of trial related injury or unclear carve outs for site negligence can result in sponsors assuming responsibility for events that are only indirectly tied to the investigational product.
At the same time, investigator and site obligations play an equally important role. Clear requirements around protocol adherence, safety reporting, and product handling help establish the standard of care. When those expectations are vague or defined inconsistently, it becomes more difficult to demonstrate whether and how a deviation occurred if a claim arises.
Another common gap emerges with third-party involvement. Trials can rely heavily on CROs, home health providers, and digital platforms, yet their responsibilities are not always fully aligned with the obligations set forth in CTAs. This can lead to fragmented responsibility while liability remains concentrated with the sponsor.
From a liability perspective, CTAs correspond directly to the elements of a negligence claim which include duty, breach, causation, and damages. The agreement effectively defines what each party is expected to do, and those definitions can either support or undermine a defense depending on how clearly they are drafted.
For life sciences companies, the key takeaway is that CTAs should not be approached as routine contracting exercises. They are risk allocation tools that should reflect how the trial will actually operate in practice. CTAs will not eliminate liability, but they can significantly influence how it is distributed and defended. Sponsors that treat these agreements as a first line of liability defense, rather than a formality, are better positioned when issues arise.
Sponsors should consider conducting a targeted review of their CTA templates to ensure that indemnification, site obligations, and third-party responsibilities align with the actual risk profile of their trials. Engaging legal and risk management early in the contracting process can help identify gaps before they translate into exposure.